Skip to main content
. Author manuscript; available in PMC: 2022 Apr 18.
Published in final edited form as: Gut. 2020 Aug 26;70(4):796–802. doi: 10.1136/gutjnl-2020-322129

Figure 1.

Figure 1

Overview of the most common EIM and their biological, small-molecule treatment options. EIM, extraintestinal manifestation; IL, interleukin; JAK, Januskinase; TNF, tumour necrosis factor; Vedo, vedolizumab.